Description

Simple

A medication used to treat a dry cough.

Clinical

An NMDA receptor antagonist used to treat cases of dry cough.

Overview

The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.

Pharmacology

Indication

For treatment and relief of dry cough.

Pharmacodynamic

Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competit... Read more

Mechanism of action

Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly... Read more

Absorption

Rapidly absorbed from the gastrointestinal tract.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

3-6 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

  • Take with or without food. The absorption is unaffected by food.

Interactions

Type in a drug name to check for interaction with Dextromethorphan
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be decreased when combined with Dextromethorphan.
(S)-Warfarin
The metabolism of (S)-Warfarin can be decreased when combined with Dextromethorphan.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
The metabolism of Dextromethorphan can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
1,10-Phenanthroline
The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dextromethorphan.
Abatacept
The metabolism of Dextromethorphan can be increased when combined with Abatacept.
Abiraterone
The metabolism of Dextromethorphan can be decreased when combined with Abiraterone.
Acalabrutinib
The metabolism of Dextromethorphan can be decreased when combined with Acalabrutinib.
Acebutolol
The metabolism of Dextromethorphan can be decreased when combined with Acebutolol.
Acenocoumarol
The metabolism of Acenocoumarol can be decreased when combined with Dextromethorphan.
Acepromazine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aceprometazine.
Acetazolamide
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acetazolamide.
5 References
  1. 1 . Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70.PubMed: 15505150
  2. 2 . Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989 Jun 16;244(4910):1360-2.PubMed: 2660263
  3. 3 . Hargreaves RJ, Hill RG, Iversen LL: Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-9.PubMed: 7976530
  4. 4 . Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL: Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. Neurotoxicology. 2007 Jul;28(4):813-8. Epub 2007 Apr 6.PubMed: 17573115
  5. 5 . Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ: Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000 Jun;293(3):962-7.PubMed: 10869398